Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients

Carlos King Ho Wong1,2,3†, David Tak Wai Lui4†, Xi Xiong1†, Celine Sze Ling Chu3,5,6, Francisco Tsz Tsun Lai1,3, Xue Li1,3,4, Eric Yuk Fai Wan1,2,3, Ching Lung Cheung1,3, Chi Ho Lee4, Yu Cho Woo4, Ivan Chi Ho Au1, Matthew Shing Hin Chung1, Franco Wing Tak Cheng1, Kathryn Choon Beng Tan4 and Ian Chi Kei Wong1,3,7,8*

Abstract

Background: In view of accumulating case reports of thyroid dysfunction following COVID-19 vaccination, we evaluated the risks of incident thyroid dysfunction following inactivated (CoronaVac) and mRNA (BNT162b2) COVID-19 vaccines using a population-based dataset.

Methods: We identified people who received COVID-19 vaccination between 23 February and 30 September 2021 from a population-based electronic health database in Hong Kong, linked to vaccination records. Thyroid dysfunction encompassed anti-thyroid drug (ATD)/levothyroxine (LT4) initiation, biochemical picture of hyperthyroidism/hypothyroidism, incident Graves’ disease (GD), and thyroiditis. A self-controlled case series design was used to estimate the incidence rate ratio (IRR) of thyroid dysfunction in a 56-day post-vaccination period compared to the baseline period (non-exposure period) using conditional Poisson regression.

Results: A total of 2,288,239 people received at least one dose of COVID-19 vaccination (57.8% BNT162b2 recipients and 42.2% CoronaVac recipients). 94.3% of BNT162b2 recipients and 92.2% of CoronaVac recipients received the second dose. Following the first dose of COVID-19 vaccination, there was no increase in the risks of ATD initiation (BNT162b2: IRR 0.864, 95% CI 0.670–1.114; CoronaVac: IRR 0.707, 95% CI 0.549–0.912), LT4 initiation (BNT162b2: IRR 0.911, 95% CI 0.716–1.159; CoronaVac: IRR 0.778, 95% CI 0.618–0.981), biochemical picture of hyperthyroidism/hypothyroidism, incident Graves’ disease (GD), and thyroiditis. Similarly, following the second dose of COVID-19 vaccination, there was no increase in the risks of ATD initiation (BNT162b2: IRR 0.972, 95% CI 0.770–1.227; CoronaVac: IRR 0.879, 95% CI 0.693–1.116), LT4 initiation (BNT162b2: IRR 1.019, 95% CI 0.833–1.246;...
Background
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected close to 500 million people and caused about 6.1 million deaths [1]. COVID-19 vaccination is essential in bringing the COVID-19 pandemic under control and minimising the serious health consequences among COVID-19 patients [2]. Studies have evaluated the inter-relationship between COVID-19 and thyroid dysfunction [3]: non-thyroidal illness syndrome, thyroiditis, Graves’ disease (GD), and Hashimoto’s thyroiditis. The onset of GD and Hashimoto’s thyroiditis after the diagnosis of COVID-19 raised the concern of SARS-CoV-2 in inducing autoimmune thyroid disorders [4, 5]. This postulation is supported by the expression of angiotensin-converting enzyme 2 (ACE2), the functional receptor for SARS-CoV-2, in many endocrine organs, including the thyroid [6].

It remains to be determined whether COVID-19 vaccination may be associated with incident thyroid dysfunction by the same token. CoronaVac is an example of inactivated vaccines, which contain an inactivated form of SARS-CoV-2. On the other hand, BNT162b2 (equivalent to Pfizer-BioNTech mRNA vaccine) stimulates the production of SARS-CoV-2 spike protein. These may in turn interact with the thyroid via ACE2. Indeed, there is an increasing number of case reports of incident thyroid dysfunction after COVID-19 vaccination [7]. These include cases of subacute thyroiditis after various COVID-19 vaccines, GD mostly after mRNA [7] and occasionally after adenovirus-vectored vaccine [8], and recently overt hypothyroidism after mRNA vaccine [9]. Molecular mimicry and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) are the postulated mechanisms for thyroid dysfunction with clinical manifestations of hyperthyroidism or hypothyroidism after COVID-19 vaccination [9–11]. A recent study has demonstrated the cross-reactivity of SARS-CoV-2 spike protein, nucleoprotein, and membrane protein with thyroid peroxidase, and the sequence homology/similarity between many thyroid peroxidase peptide sequences and sequences in various SARS-CoV-2 proteins [10].

Conclusions: Our population-based study showed no evidence of vaccine-related increase in incident hyperthyroidism or hypothyroidism with both BNT162b2 and CoronaVac.

Keywords: COVID-19 vaccines, BNT162b2 vaccine, Vaccines, Inactivated, Hyperthyroidism, Hypothyroidism, Graves’ disease, Thyroiditis

Methods
Data source
Since 23 February 2021, the COVID-19 Vaccination Programme has been launched in Hong Kong, and vaccination records have been reported to the Department of Health (DH) daily. All active patients’ electronic medical records (EMRs) between 1 January 2018 and 30 September 2021 were extracted from the Hong Kong Hospital Authority (HA) and cross-linked with vaccination records by hashed unique identifiers. This vaccine safety data linkage is largely representative of the Hong Kong population as HA is the only provider of public healthcare services, which provides medical services for 90% of all primary, secondary, and tertiary care services.
of Hong Kong with a population of more than 7 million [13]. EMRs provided by HA are generated during public healthcare services. Available information includes demographics, date of registered death, drug dispensing records, diagnoses, procedures, and laboratory tests. All prescriptions dispensed by HA pharmacies are recorded. These two linked data sources have been recently used to conduct population-based pharmacovigilance studies of COVID-19 vaccines [14–27].

The study received ethical approval from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 21-149 and UW 21-138); and the Department of Health Ethics Committee (LM 21/2021).

Study design
We conducted an SCCS study to evaluate the associations between COVID-19 vaccines and incident thyroid dysfunction during the COVID-19 Vaccination Programme in Hong Kong. SCCS was designed to evaluate the relative incidence of outcome events at defined risk periods compared with baseline periods among people with outcome events during the observation period [28]. The advantages of this study design are that individuals’ comparison removes the potential confounding effect of all time-invariant variables during the study period. This methodology has been used to estimate COVID-19 vaccine safety in neurological, thrombocytopenic, thromboembolic and haemorrhagic events, haematological disorders, and herpes zoster-related hospitalizations [19, 20, 29–32].

Study population
People aged ≥ 18 years who used any HA services between 1 January 2018 and 30 September 2021 were identified from the vaccine safety data linkage. We excluded people who (i) received a heterologous COVID-19 vaccine regime and (ii) were polymerase chain reaction-tested positive for SARS-CoV-2 from 23 January 2020 (the first COVID-19 case in Hong Kong) to 30 September 2021. We also excluded people who had history of ATD and LT4 prescription records, abnormal thyroid-stimulating hormone (TSH) levels, GD, or thyroiditis within the 3 years before the observation period.

Outcomes of interest: thyroid dysfunction
Study outcomes were initiation of ATD, initiation of LT4, hyperthyroidism, hypothyroidism, GD, and thyroiditis. We identified ATD and LT4 prescriptions using British National Formulary (BNF) code and drug names from EMRs (ATD: BNF 6.2.2; LT4: BNF 6.2.1). Initiation of ATD was taken to represent incident hyperthyroidism, while initiation of LT4 was taken to represent incident hypothyroidism. Hyperthyroidism was defined by TSH < 0.35 mIU/L, while hypothyroidism by TSH > 4.8 mIU/L. The International Classification of Diseases-9 (ICD-9) codes was used to identify GD (ICD-9: 242.00 and 242.01) and thyroiditis (ICD-9: 245.x).

Exposure
The observation period was from 23 February 2021 to 30 September 2021. The exposure was the first or second dose of CoronaVac or BNT162b2 vaccines. Based on reviews of published case reports on subacute thyroiditis and GD after COVID-19 vaccination showing that the onset of thyroid dysfunction could occur from several days to up to 8 weeks post-vaccination [33, 34], the exposure period was defined as a risk window of 56 days post-vaccination. For people who received the second dose before day 56, the period before the second dose was considered as post-first dose exposure, while the period after the second dose was considered as post-second dose exposure. The remaining periods during the observation period were classified as the baseline period (non-exposure period). A typical observation period of a vaccinated individual is shown in Fig. 1.

Statistical analyses
Incidence of thyroid dysfunction
For CoronaVac and BNT162b2 recipients, the number of events per 100,000 doses, and crude incidence rates per 100,000 person-years after the first and second doses was estimated. The follow-up period began from the date of each dose and was censored on the date of death, 56 days, end of the study period, or date of the second dose (for first dose recipients), whichever occurred first.

SCCS analysis
The SCCS model was applied to estimate the incidence rate ratios (IRRs) with the corresponding 95% confidence intervals (CI) of each outcome. Whether the SCCS models are appropriate relies on three key assumptions. (i) Recurrent events must be independent. The occurrence of the first event should not influence the likelihood of the subsequent event. Thus, we only treat the first episode as the outcome of interest in our analysis [35]. (ii) Occurrence of an event should not alter the probability of subsequent exposure. Histograms of the number of events by the interval between the date of each dose (exposure date) and event day are illustrated in Additional file 1: Fig. S1. For example, if patients were initiated on ATD before vaccination, they might be less likely to receive the vaccines. It would lead to a low rate of events right before vaccination and increase the relative rate of events occurring in the risk period versus the baseline period. (iii) Event should not censor observation periods.
Thus, we conducted the analysis using the modified SCCS model “eventdepenexp” in the R-package “SCCS” [36]. The use of the modified SCCS in COVID-19 vaccine research has been comprehensively discussed in a recent publication [37]. The modified SCCS requires including unvaccinated people during the observation period to inform the timing of the events by adjusting for the monthly seasonal effects.

Subgroup analyses were conducted by age (< 65 vs ≥ 65 years) among men and women separately due to different sex distributions between the younger and older. Sensitivity analyses were conducted (i) by varying the risk periods from the first dose to 42, 35, 28, and 21 days after the first dose, or from the second dose to 42, 35, 28, and 21 days after the second dose, and (ii) by excluding the pre-vaccination period due to the possible increase in diagnosis of thyroid dysfunction when the vaccinated individuals had thyroid function tests prior to vaccination.

Two-sided \( p \) values of < 0.05 were considered statistically significant. Statistical analyses were independently conducted and cross-checked by co-authors (XX, MSHC, ICHA, and FWTC) for quality assurance. All analyses were performed in R version 4.1.0 (R Foundation for

---

**Fig. 1** Schematic presentation of the observation period of COVID-19 vaccine recipients in the self-controlled case series study
Results
A total of 1,321,753 and 966,486 people received at least one dose of BNT162b2 and CoronaVac, respectively, from 23 February to 30 September 2021 (Additional file 1: Fig. S2). 94.3% of BNT162b2 recipients and 92.2% of CoronaVac recipients completed two doses of vaccine within the study period. The mean age, Charlson comorbidity index, and proportion of men were 45.6 years (SD: 16.1), 1.4 (SD: 1.5) and 45.1% in the BNT162b2 group, and 55.4 (SD: 14.2), 2.2 (SD: 1.5) and 46.5% in the CoronaVac group, respectively. Baseline characteristics of vaccinated people who developed outcomes of ATD initiation, LT4 initiation, incident hyperthyroidism, incident hypothyroidism, GD, and thyroiditis are summarised in Additional file 1: Table S1.

Incidence of thyroid dysfunction
Regarding thyrotoxicosis-related outcomes, the incidences of biochemical hyperthyroidism, ATD initiation, GD, and thyroiditis were 35.4, 22.6, 1.6, and 0.5 cases per 100,000 doses within 56 days following the first dose of BNT162b2; 65.9, 41.4, 1.8, and 0.4 cases per 100,000 doses following the second dose of BNT162b2; 47.4, 25.1, 0.4, and 0.4 cases per 100,000 doses following the first dose of CoronaVac; and 73.5, 46.0, 1.9, and 0.7 cases per 100,000 doses following the second dose of CoronaVac (Additional file 1: Table S2).

Regarding hypothyroid-related outcomes, the incidences of biochemical hypothyroidism and LT4 initiation were 26.5 and 21.3 cases per 100,000 doses following the first dose of BNT162b2, 46.9 and 48.2 cases per 100,000 doses following the second dose of BNT162b2, 36.8 and 33.2 cases per 100,000 doses following the first dose of CoronaVac, and 52.0 and 49.5 cases per 100,000 doses following the second dose of CoronaVac.

Table 1
Risks of thyroid dysfunction in the 56-day risk period following the first or second dose of COVID-19 vaccination

| Outcomes                  | CoronaVac | BNT162b2 |
|---------------------------|-----------|----------|
|                           | No. of event | Person years | IRR (95% CI) | No. of event | Person years | IRR (95% CI) |
| Initiation of ATD         |            |           |              |              |           |              |
| Baseline                  | 3116       | 1878.3    | 1.00 -       | 3299         | 2000.0     | 1.00 -       |
| 0 to 55 days: first dose  | 109        | 74.5      | 0.707 (0.549, 0.912) | 130         | 76.4       | 0.864 (0.670, 1.114) |
| 0 to 55 days: second dose | 182        | 99.3      | 0.879 (0.695, 1.116) | 216         | 119.1      | 0.972 (0.770, 1.227) |
| Initiation of LT4         |            |           |              |              |           |              |
| Baseline                  | 5315       | 3131.6    | 1.00 -       | 5575         | 3280.4     | 1.00 -       |
| 0 to 55 days: first dose  | 167        | 125.6     | 0.778 (0.618, 0.981) | 144         | 118.6      | 0.911 (0.716, 1.159) |
| 0 to 55 days: second dose | 217        | 175.4     | 0.768 (0.613, 0.962) | 288         | 219.2      | 1.019 (0.833, 1.246) |
| Hyperthyroidism (TSH < 0.35 mIU/L) |        |           |              |              |           |              |
| Baseline                  | 11423      | 6896.8    | 1.00 -       | 11781        | 7141.6     | 1.00 -       |
| 0 to 55 days: first dose  | 354        | 214.5     | 0.830 (0.713, 0.967) | 345         | 201.5      | 0.872 (0.744, 1.023) |
| 0 to 55 days: second dose | 505        | 286.5     | 0.911 (0.786, 1.055) | 619         | 333.6      | 1.039 (0.899, 1.201) |
| Hypothyroidism (TSH > 4.8 mIU/L) |        |           |              |              |           |              |
| Baseline                  | 8707       | 5250.1    | 1.00 -       | 8941         | 5419.6     | 1.00 -       |
| 0 to 55 days: first dose  | 300        | 172.3     | 0.963 (0.807, 1.149) | 307         | 158.9      | 1.002 (0.838, 1.199) |
| 0 to 55 days: second dose | 380        | 231.6     | 0.945 (0.799, 1.119) | 463         | 270.7      | 0.935 (0.794, 1.102) |
| Graves’ disease           |            |           |              |              |           |              |
| Baseline                  | 288        | 171.9     | 1.00 -       | 325          | 199.5      | 1.00 -       |
| 0 to 55 days: first dose  | 3          | 5.2       | NA NA        | 21           | 9.0        | 1.105 (0.534, 2.289) |
| 0 to 55 days: second dose | 15         | 7.2       | NA NA        | 21           | 12.6       | 0.823 (0.424, 1.599) |
| Thyroiditis               |            |           |              |              |           |              |
| Baseline                  | 60         | 37.0      | 1.00 -       | 60           | 38.2       | 1.00 -       |
| 0 to 55 days: first dose  | 4          | 2.1       | NA NA        | 6            | 1.7        | NA NA        |
| 0 to 55 days: second dose | 6          | 3.0       | NA NA        | 5            | 2.9        | NA NA        |

ATD anti-thyroid drug, LT4 levothyroxine, IRR incidence rate ratio, CI confidence interval, TSH thyroid-stimulating hormone, NA not available if the number of events in one of the risk periods were \( \leq 5 \).
Risk of thyroid dysfunction

Table 1 summarises the outcomes of thyroid dysfunction among the vaccine recipients. The IRRs for thyrotoxicosis-related outcomes of interest compared to the baseline period indicated no significant increase in the risk of biochemical hyperthyroidism (BNT162b2: IRR = 0.872, 95% CI: 0.744–1.023; CoronaVac: IRR = 0.830, 95% CI: 0.713–0.967) and initiation of ATD (BNT162b2: IRR = 0.864, 95% CI: 0.670–1.114; CoronaVac: IRR = 0.707, 95% CI: 0.549–0.912) related to the first doses of COVID-19 vaccine. There was no significant increase in the incidence of GD or thyroiditis following the first dose of either type of COVID-19 vaccination. The IRRs for these outcomes of interest compared to the baseline period indicated no significant increase in the risk of biochemical hypothyroidism (BNT162b2: IRR = 1.039, 95% CI: 0.899–1.201; CoronaVac: IRR = 0.911, 95% CI: 0.786–1.055), initiation of ATD (BNT162b2: IRR = 0.972, 95% CI: 0.770–1.227; CoronaVac: IRR = 0.879, 95% CI: 0.693–1.116) related to the second doses of COVID-19 vaccine. There was no significant increase in the incidence of GD or thyroiditis following the second dose of either type of COVID-19 vaccination.

The IRRs for hypothyroid-related outcomes of interest compared to the baseline period indicated no significant increase in the risk of biochemical hypothyroidism (BNT162b2: IRR = 1.002, 95% CI: 0.838–1.199; CoronaVac: IRR = 0.963, 95% CI: 0.807–1.149), initiation of LT4 (BNT162b2: IRR = 0.911, 95% CI: 0.716–1.159; CoronaVac: IRR = 0.778, 95% CI: 0.618–0.981) related to the first doses of COVID-19 vaccine. The IRRs for these outcomes of interest compared to the baseline period indicated no significant increase in the risk of hypothyroidism-related outcomes related to both doses of COVID-19 vaccines. The IRRs for these outcomes of interest compared to the baseline period indicated no significant increase in the risk of biochemical hypothyroidism (BNT162b2: IRR = 0.935, 95% CI: 0.794–1.102; CoronaVac: IRR = 0.945, 95% CI: 0.799–1.119) and initiation of LT4 (BNT162b2: IRR = 1.019, 95% CI: 0.833–1.246; CoronaVac: IRR = 0.768, 95% CI: 0.613–0.962) related to the second doses of COVID-19 vaccine.

The results of the subgroup and sensitivity analyses were consistent with the main analysis (Additional file 1: Tables S3-S9). There was no change in the results when the risk period was shortened to as early as 3 weeks post-vaccination.

Discussion

This is the first population-based study of the risk of incident thyroid dysfunction associated with COVID-19 vaccination. We did not observe any major signal of increased risks of incident thyroid dysfunction within 56 days of the first and second doses of both mRNA and inactivated COVID-19 vaccines. Thyroid dysfunction following COVID-19 vaccination was rare.

Following the report of the first cases of GD post-COVID-19 vaccination in May 2021 [38], many case reports of various thyroid dysfunction have been published: not limited to GD, but also subacute thyroiditis and hypothyroidism. The temporal relationship was the main reason to believe that these events were related to COVID-19 vaccination. Invariably, the commonly postulated mechanisms linking COVID-19 vaccination and thyroid dysfunction for all these cases included molecular mimicry [10], and ASIA [11]. Nonetheless, case reports or series are not able to estimate absolute risks and examine association between COVID-19 vaccination and thyroid dysfunction. Our population-based SCCS analysis suggested no excess in risk of GD in the 56 days following the first and second doses of either type of COVID-19 vaccination, reflected in several ways in our results. Firstly, we did not observe an increased risk of biochemical diagnosis of thyrotoxicosis. Thyrotoxicosis is most commonly due to primary hyperthyroidism and, less commonly, destructive thyroiditis. GD accounts for 60–80% of cases of primary hyperthyroidism [39]. As GD incidence varies with age and sex (peaks at 30–50 years of age and is more common in females) [40], we performed age- and sex-specific subgroup analyses, which consistently showed the neutral association between COVID-19 vaccination and the risks of thyrotoxicosis. Secondly, there was no increase in the rate of ATD initiation after COVID-19 vaccination was observed. ATD initiation largely represents the occurrence of incident GD, since GD is the most common aetiology of primary hyperthyroidism. Thirdly, the incidence of diagnostic coding of GD was not increased in association with COVID-19 vaccination. In line with our findings, a recent case series reported that most patients who developed GD after the first dose of COVID-19 vaccination received the subsequent dose of vaccination without instability in thyroid function [41]. Furthermore, all these cases of COVID-19 vaccine-related GD share similar features as the typical GD seen in our clinical practice—in terms of demographics, clinical features, and management. All cases of GD post-vaccination were easily controlled with ATD [34]. All these suggested that the reported cases of GD following COVID-19 vaccination may merely be coincidence in timing, while the preponderance of GD associated with mRNA vaccination may be due to the higher coverage of that type of vaccine [12].

In addition, our study did not suggest an increased risk of thyroiditis associated with COVID-19 vaccination, as we did not observe an increased risk of biochemical diagnosis of hyperthyroidism, nor an increased risk of
diagnostic coding of thyroiditis. A review of the available cases showed no predilection of the occurrence of subacute thyroiditis after the first and second dose of COVID-19 vaccines [42]. A recent case series showed that patients who developed subacute thyroiditis after COVID-19 vaccination proceeded to the subsequent dose without recurrence [43]. Furthermore, a single-centre analysis in Turkey revealed no significant increase in the number of events of subacute thyroiditis before and after commencement of the nationwide COVID-19 vaccination programme [42]. Last but not least, a recent study of 72 healthy individuals in Greece showed no clinically significant change in thyroid function, anti-thyroid peroxidase and anti-thyroglobulin antibody titres up to one month after the second dose of mRNA COVID-19 vaccines [44]. Hence, there is yet strong evidence to support the causal relationship between subacute thyroiditis and COVID-19 vaccination.

Our study also showed no increase in the incidence of biochemical diagnosis of hypothyroidism (comprising both subclinical and overt hypothyroidism) and the LT4 initiation (reflecting clinically significant hypothyroidism). Indeed, among the many reports of thyroid dysfunction following COVID-19 vaccination, there was only one report of overt hypothyroidism following mRNA vaccination [9]. Together with the abovementioned cohort study performed in Greece [44], all these reassure that COVID-19 vaccination does not lead to hypothyroidism.

Our study has several strengths. Firstly, it is the first study to quantify the risk of thyroid dysfunction following COVID-19 vaccination using a population-based dataset. Secondly, we analysed the risk of thyroid dysfunction among recipients of two different types of COVID-19 vaccines. Thirdly, the modified SCCS model minimised the measured or unmeasured time-invariant confounders and ensured that the analysis did not violate the assumption of independence between outcome and exposure. Our results showed that the risk of thyroid dysfunction following COVID-19 vaccination was not higher than in the baseline period. Vaccinated individuals in Hong Kong might have thyroid function tests and health checks prior to the vaccination and have a higher chance of detecting hyperthyroidism and hypothyroidism or initiation ATD and LT4 during the pre-vaccination period. We demonstrated the robustness of our results by removing the pre-vaccination period in the sensitivity analysis, showing consistent results (Additional file 1: Table S9). However, our results should be interpreted bearing certain limitations. Firstly, given the limitations of the electronic health database, GD and thyroiditis were identified using diagnostic codes and inferred by the biochemical diagnosis of hyperthyroidism and initiation of ATD. Anti-thyroid antibodies were not systematically evaluated. Ultrasonographic and scintigraphic features were not available in our dataset. Hence, the incidence of GD might be underestimated. However, it was unlikely to affect our conclusion because of the nature of SCCS design comparing incidence rate of thyroid dysfunction between post-vaccination and baseline periods. Secondly, using TSH to capture thyroid dysfunction might have included cases of secondary hyperthyroidism and hypothyroidism, though these were expected to be uncommon. Thirdly, people who did not seek medical attention for subclinical thyroid problems might not be captured. Nevertheless, only clinically overt thyroid dysfunction is relevant and concerns potential COVID-19 vaccine recipients. Last but not least, the risk of GD associated with the heterologous COVID-19 vaccination regime is not addressed in our current study. Three cases of GD were reported after a booster dose (two mRNA vaccines and one adenovirus-vectored vaccine) following two doses of inactivated COVID-19 vaccines [43, 45]. Future surveillance data are warranted to specifically evaluate the potential of heterologous COVID-19 vaccination in inducing GD.

Conclusions

Despite a large number of case reports on thyroid dysfunction following COVID-19 vaccination, our study showed that CoronaVac (inactivated whole-virus vaccine) and BNT162b2 (mRNA vaccine) vaccination was unlikely to be associated with increased risks of incident hyperthyroidism or hypothyroidism. Thyroid dysfunction following COVID-19 vaccination was rare.

Abbreviations

ACE2: Angiotensin-converting enzyme 2; ASIA: Autoimmune/inflammatory syndrome induced by adjuvants; ATD: Antithyroid drug; BNF: British National Formulary; BNT162b2: mRNA COVID-19 vaccine; CI: Confidence intervals; CoronaVac: Inactivated COVID-19 vaccine; COVID-19: Coronavirus disease 2019; DH: Department of Health; EMRs: Electronic medical records; GD: Graves’ disease; HA: Hospital Authority; ICD-9: The International Classification of Diseases-9 codes; IRR: Incidence rate ratio; LT4: Levothyroxine; NA: Not available; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SCCS: Self-controlled case series; SD: Standard deviation; TSH: Thyroid-stimulating hormone.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02548-1.

Additional file 1: Figure S1. Histograms of number of thyroid dysfunction events by interval between vaccination date and event date by vaccines and doses. Pink area shows the 56 days after vaccination. Figure S2. Study flow diagram. Table S1. Baseline characteristics of people who experienced the individual outcomes by types of vaccine between 23 February 2021 and 30 September 2021. Table S2. Crude incidence rate and incidence of thyroid dysfunction within 56-day following the first or second dose of COVID-19 vaccination. Table S3. Risks of thyroid dysfunction in the 56-day risk period following the first or second dose of COVID-19 vaccination.
COVID-19 vaccination by age group among men (age <65 vs ≥65 years).

Table S4. Risks of thyroid dysfunction in the 56-day risk period following the first or second dose of COVID-19 vaccination by age group among women (age <65 vs ≥65 years).

Table S5. Risks of thyroid dysfunction in the 42-day risk period following the first or second dose of COVID-19 vaccination.

Table S6. Risks of thyroid dysfunction in the 35-day risk period following the first or second dose of COVID-19 vaccination.

Table S7. Risks of thyroid dysfunction in the 28-day risk period following the first or second dose of COVID-19 vaccination.

Table S8. Risks of thyroid dysfunction in the 21-day risk period following the first or second dose of COVID-19 vaccination.

Table S9. Risks of thyroid dysfunction in the 14-day risk period following the first or second dose of COVID-19 vaccination after restricting analysis to the period after vaccination.

Acknowledgements
The authors thank the Hospital Authority and the Department of Health for the generous provision of data for this study. F.T.T.L and I.C.K.W’s post were partly funded by D24H; hence this work was partly supported by AR@InnoHK administered by Innovation and Technology Commission.

Authors’ contributions
C.K.H.W, D.T.W.L, and X.X reviewed the literature, designed the statistical analysis, conducted the analyses, and wrote the manuscript. C.K.H.W, D.T.W.L, and X.X reviewed the literature, contributed to the interpretation of the analysis, and wrote the manuscript. X.X, I.C.H.A, M.S.H.C, and F.W.T.C, conducted the analyses. C.K.H.W, D.T.W.L, C.S.L.C, F.T.T.L, X.L, E.Y.F.W, C.L.C, C.H.L., Y.C.W, K.C.B.T, and I.C.K.W contributed to the interpretation of the analysis and critically reviewed and revised the manuscript. All authors contributed to the interpretation of the analysis, critically reviewed and revised the manuscript, and approved the final manuscript as submitted. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors read and approved the final manuscript.

Funding
Research Grant from the Food and Health Bureau, the Government of the Hong Kong Special Administrative Region (Ref. No. COVID19F01). The funders did not have any role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials
The data that support the findings of this study were extracted from the Hospital Authority database in Hong Kong. Restrictions apply to the availability of these data, which were used under license for this study. Data sharing is prohibited by the Hospital Authority. All the analysis codes that support the findings are available from the corresponding author upon reasonable requests.

Declarations
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 21-149 and UW 21-138), and the Department of Health Ethics Committee (LM 21/2021). All data were anonymised, and the project was granted waiver of participant consent.

Consent for publication
Not applicable.

Competing interests
Carlos King Ho Wong reports receipt of research funding from the EuroQol Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. Francesco Tsz Tsun Lai has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council. Xue Li has received research grants from the Food and Health Bureau of the Government of the Hong Kong SAR, research and educational grants from Janssen and Pfizer, internal funding from University of Hong Kong, and consultancy fee from Merck Sharp & Dohme, unrelated to this work. Eric Yuk Fai Wan has received research grants from the Food and Health Bureau of the Government of the Hong Kong SAR and the Hong Kong Research Grants Council, outside the submitted work. Celine Sze Ling Chui has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen, and personal fee from Primevigilance Ltd., outside the submitted work. Esther Wai Yin Chan reports honorarium from Hospital Authority, grants from Research Grants Council (RGC, Hong Kong), grants from Research Fund Secretariat of the Food and Health Bureau, grants from National Natural Science Fund of China, grants from Wellcome Trust, grants from Bayer, grants from Bristol-Myers Squibb, grants from Pfizer, grants from Janssen, grants from Amgen, grants from Takeda, and grants from Narcotics Division of the Security Bureau of HKSSAR, outside the submitted work. Ian Chi Kei Wong reports research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong RGC, and the Hong Kong Health and Medical Research Fund, National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, and also received speaker fees from Janssen and Medice in the previous 3 years, all outside the submitted work.

Author details
1 Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2 Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 3 Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong SAR, China. 4 Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 5 School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 6 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 7 Research Department of Practice and Policy, UCL School of Pharmacy, University College London, London, UK. 8 Aston School of Pharmacy, Aston University, Birmingham, UK.

Received: 22 June 2022 Accepted: 1 September 2022 Published online: 14 October 2022

References
1. World Health Organization. WHO coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 24 Mar 2022.
2. Haque A, Pant AB. Mitigating COVID-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. J Autoimmun. 2022;127:102792.
3. Inaba H, Azawa T. Coronavirus disease 2019 and the thyroid - progress and perspectives. Front Endocrinol (Lausanne). 2021;12:70833.
4. Murugan AK, Alzahrani AS. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease. Endocrinology. 2021;73(2):243–54.
5. Knack RS, Hanada T, Knack RS, Mayr K. Hashimoto’s thyroiditis following SARS-CoV-2 infection. BMJ Case Rep. 2021;14(8):e244909.
6. Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43(7):1027–31.
7. Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front Public Health. 2021;9:778964.
8. Di Filippo L, Castellino L, Giuschina A. Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients. Endocrine. 2022;51(1):19–21.
9. Giusti M, Maio A. Acute thyroid swelling with severe hypothyroid myxoedema after COVID-19 vaccination. Clinic Case Rep. 2021;9(12):e05217.
10. Vojdani A, Vojdani E, Kharazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020;11:617089.
11. Wadat A, David P, Brown S, Shinfield Y. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne). 2016;7:150.
12. Jafarzadeh A, Nemati M, Jafarzadeh S, Nozari P, Mortazavi SM. Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence. J Endocrinol Invest. 2022;1–29. https://doi.org/10.1007/s40618-022-01786-7.

13. Cheung KS, Chen L, Chan EW, Seto WK, Wong IC, Leung WK. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gastroenterology. 2019;168(1):100–105.

14. Xiong X, Wong CKH, Au ICH, Lai FTT, Li X, Wan YEF, et al. Effectiveness of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022;32(5):505–14.

15. Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2022;81(4):564–8.

16. Wan YEF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan YKC, et al. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64–72.

17. Chua GT, Kwan MYW, Chui CSL, Smith RD, Cheung EC, Tian T, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comitamy vaccination. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciaa989.

18. Lai FTT, Li X, Peng K, Huang L, Ip P, Tong X, et al. Cardits after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study. Lancet. 2021;398(10307):1061–70.

19. Sing CW, Tang CTA, Chui CSL, Fan M, Lai FTT, Li X, et al. COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case studies. Am J Hematol. 2022;97(4):470–80.

20. Wan YEF, Chui CSL, Wang Y, Ng WVS, Yan YKC, Lai FTT, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. J Infect. 2022;84(3):443–8.

21. Wong CKH, Ong L, Lau KTK, Chui CSL, Lai FTT, Li X, et al. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization. BMC Med. 2022;20(1):119.

22. Lai FTT, Huang L, Chui CSL, Wan YEF, Li X, Wong CKH, et al. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun. 2022;13(1):411.

23. Lai FTT, Huang L, Peng K, Li X, Chui CSL, Wan YEF, et al. Post-COVID-19 vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med. 2022;291(6):864–9.

24. Lai FTT, Chua GT, Chan EWY, Huang L, Kwan MYW, Ma T, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11(1):885–93.

25. Li X, Tong X, Wong IC, Peng K, Chui CSL, Lai FTT, et al. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022. https://doi.org/10.1136/gutjnl-2021-326860.

26. Chui CSL, Fan M, Wan YEF, Leung MTY, Cheung E, Yan YKC, et al. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine. 2022;50:101504.

27. Wong CKH, Mak LY, Au ICH, Lai FTT, Li X, Wan YEF, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022. https://doi.org/10.1016/j.jhep.2022.06.032.

28. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996;143(11):1165–73.

29. Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931.

30. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thromboembolic, thrombocytopenic, and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290–7.

31. Li X, Raventós B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. 2022;376:e68637.

32. Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144–53.

33. Sahin Teken M, Saylosy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report. Hum Vaccin Immunother. 2021;17(11):4090–2.

34. Zettling G, Krebs M. Two further cases of Graves' disease following SARS-CoV-2 vaccination. J Endocrinol Invest. 2022;25(1):227–8.

35. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515.

36. Yonas GW, Heathier W, Paddy F. The self-controlled case series method: The Comprehensive R Archive Network; 2022. https://cran.r-project.org/web/packages/SCCS/SCCS.pdf. Accessed 24 Aug 2022.

37. Ghembriemchel-Weldeslassie Y, Jabbagji MB, Botton J, Bertrand M, Baricault B, Drouin J, et al. A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety. Stat Med. 2022;41(10):1735–50.

38. Vera-Larstra O, Ordinola Navarro A, Cruz Dominguez MF, Medina G, Sánchez Valdecasas D, Jara LFI, et al. Two cases of Graves' disease following SARS-CoV-2 vaccine: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021;31(9):1436–9.

39. Pokhrel B, Bhusal K. Graves' disease: StatPearls Publishing. Treasure Island (FL); 2022.

40. Smith TJ, Hagedus L. Graves' disease. N Engl J Med. 2016;375(16):1552–65.

41. Chee YJ, Liew H, Hoi WH, Lee Y, Lim B, Chin HX, et al. SARS-CoV-2 mRNA vaccination and Graves' disease: a report of 12 cases and review of the literature. J Clin Endocrinol Metab. 2022;107(6):e2324–30.

42. Yorulmaz G, Sahin Teken M. SARS-CoV-2 vaccine-associated subacute thyroiditis. J Endocrinol Investig. 2022;45(7):1341–7.

43. Oguz SH, Sendur SN, Iremli BG, Gurlek A, Erbas T, Unluturk U. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up. J Endocrinol Investig. 2022;2022.107(5):e1823–34.

44. Paschou SA, Karalis V, Psaltopoulou T, Vasileiou V, Charitaki I, Bagratuni T, et al. Patients with autoimmune thyroiditis present similar immunological response to COVID-19 BNT162b2 mRNA vaccine with healthy subjects, while vaccination may affect thyroid function: a clinical study. Front Endocrinol (Lausanne). 2022;13:840668.

45. Sriphrapradang C, Shantavasinkul PC. Graves' disease following SARS-CoV-2 vaccination. Endocrine. 2021;74(3):473–4.